X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial for MAGE-A1 positive solid tumors.
Lead Product(s): TK-8001
Therapeutic Area: Oncology Product Name: TK-8001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
TK-2504 is an HLA-A11-restricted CD8 TCR-T specific for KRAS, most frequently mutated oncogenes, and acts as a molecular switch leading to activation of many intracellular signaling pathways involved in regulation of cell growth, cell differentiation and cell death.
Lead Product(s): TK-2504
Therapeutic Area: Oncology Product Name: TK-2504
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1 showed higher affinity than human derived TCRs resulted in superior anti-tumor activity .
Lead Product(s): TK-8001
Therapeutic Area: Oncology Product Name: TK-8001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
T-knife’s lead program, TK-8001, is a novel TCR-T product candidate targeting MAGE-A1 positive cancers. T-knife Plans to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021.
Lead Product(s): TK-8001
Therapeutic Area: Oncology Product Name: TK-8001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fidelity Management & Research Company, LLC
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 02, 2021
Details:
Under the terms of the agreement, Catalent will undertake transfer of T-knife´s platform process for T-cell receptor-based cell therapy at its site in Gosselies, Belgium, with the goal of manufacturing clinical batches for European trials in 2021.
Lead Product(s): T-cell receptor-based cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 21, 2020
Details:
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties.
Lead Product(s): Humanized T-cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $78.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
